Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 543.65M P/E - EPS this Y 40.80% Ern Qtrly Grth -
Income -208.38M Forward P/E -3.73 EPS next Y 16.90% 50D Avg Chg 12.00%
Sales 1.7M PEG - EPS past 5Y - 200D Avg Chg 36.00%
Dividend N/A Price/Book 2.03 EPS next 5Y - 52W High Chg -17.00%
Recommedations 1.80 Quick Ratio 5.90 Shares Outstanding 265.93M 52W Low Chg 96.00%
Insider Own 18.04% ROA -25.35% Shares Float 91.18M Beta 1.93
Inst Own 56.99% ROE -101.61% Shares Shorted/Prior 4.07M/3.15M Price 3.13
Gross Margin - Profit Margin - Avg. Volume 730,825 Target Price 10.69
Oper. Margin -10,337.34% Earnings Date May 14 Volume 386,508 Change -0.63%
About Autolus Therapeutics plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics plc News
04/25/24 Recent 13% pullback isn't enough to hurt long-term Autolus Therapeutics (NASDAQ:AUTL) shareholders, they're still up 157% over 1 year
04/24/24 Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
04/23/24 Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
04/02/24 Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
04/01/24 Autolus Therapeutics Announces Changes to its Board of Directors
03/21/24 Q4 2023 BioNTech SE Earnings Call
03/17/24 Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript
03/15/24 Autolus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
03/15/24 Q4 2023 Autolus Therapeutics PLC Earnings Call
03/14/24 Autolus Therapeutics PLC Reports Full Year 2023 Financial Results
03/14/24 Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
03/12/24 Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
03/11/24 Autolus Therapeutics announces publication in Blood Cancer Journal
02/29/24 Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
02/22/24 Autolus Therapeutics announces publication in Nature Communications
02/21/24 Autolus Therapeutics plc's (NASDAQ:AUTL) institutional investors lost 8.1% last week but have benefitted from longer-term gains
02/15/24 Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
02/12/24 Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?
02/08/24 Autolus Announces Pricing of Underwritten Offering
02/08/24 BioNTech partners with Autolus to boost cell therapy manufacturing
AUTL Chatroom

User Image Alpha_Tau Posted - 1 day ago

$AUTL this downtrend is a big buyop for me... this reminds me of $IOVA... down 50% after PDUFA submission (6$ to 3$) before rebouncing 3months before PDUFA. Now in the teens !!!

User Image StephCasi97 Posted - 1 day ago

$AUTL

User Image yoter Posted - 2 days ago

$AUTL even if we hear no major news until November, we are in for a x2 increase in sp in anticipation of Nov. 16 FDA decision date. So this recent downtrend is a good opportunity to accumulate. Stay the course Bulls

User Image Magic8BallResponse Posted - 3 days ago

$AUTL What a shame.... seems to be down since BionT deal

User Image Mancunian Posted - 3 days ago

$AUTL Follow the science and not the daily trading

User Image _www_larval_com_ Posted - 3 days ago

$AUTL just shot 3% higher to 6% (~6Mv) moments ago, 05/17 options, follow for more volatility.

User Image Magic8BallResponse Posted - 3 days ago

$AUTL Nervous feet... pitter patter pitter patter

User Image Stocks_Advisor Posted - 04/30/24

$AUTL If it goes below 3.4 can be strong re-bounce to 4+, then will fall down further

User Image Magic8BallResponse Posted - 04/30/24

$AUTL Very odd trading. WTF?

User Image Mancunian Posted - 04/30/24

$AUTL I am expecting a very strong second half to the year with the sp reaching new highs.This drop is due to technical shorting and absolutely nothing to do with company fundamentals…..

User Image schiefe13 Posted - 04/30/24

$AUTL $3.80 is crazy. Shorts momentum is killing bios

User Image Magic8BallResponse Posted - 04/26/24

$AUTL Why the sell off? Dilution?

User Image 1LIFE2LIVE Posted - 04/25/24

$AUTL Autolus has solid collaborations with Bristol Myers (October 2022), BioNTech (2/2024 = $250M + $580M in potential milestones payments), Blackstone Life Sciences (up to $250M in 2021 = $70M in 2022), Cabaletta Bio (January 2023) & Moderna (2021 & Q4/2022) - all with potential substantial milestones. $840M on hand 3/24 “well capitalized to drive the full launch and commercialization of Obe-cel as well as to advance its pipeline development plans.” Earnings/operational updates on May 14th; June/December obe-cel data updates and PDUFA on 11/16/24. Added on this mornings weakness. Long.

User Image StephCasi97 Posted - 04/25/24

$AUTL

User Image Stocksrunner Posted - 04/24/24

📊 Key Technical Indicators & Analysis: $ALL shows promising signs as chart patterns suggest potential growth. $AUTL experiences notable movement below critical moving average, warranting attention. $BILI crosses above key moving average level, signaling possible bullish momentum. $MAT shows promise as shares cross above 200 DMA, indicating potential upward movement. $CSX becomes oversold, presenting a possible buying opportunity according to DividendRank. Stay informed with these key indicators and chart patterns for potential trading opportunities! https://stocksrunner.com/home

User Image Stock_Titan Posted - 04/24/24

$AUTL Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO https://www.stocktitan.net/news/AUTL/abstract-for-longer-term-follow-up-and-additional-data-analysis-of-dgezqflr0lt2.html

User Image RobGomes Posted - 04/23/24

$AUTL Back to 4. Fill gaps

User Image Stock_Titan Posted - 04/23/24

$AUTL Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 https://www.stocktitan.net/news/AUTL/autolus-therapeutics-to-report-first-quarter-2024-financial-results-am5ylpd0qod7.html

User Image Magic8BallResponse Posted - 04/21/24

$AUTL This is bizarre. Does the company have an ATM running or something?

User Image 1LIFE2LIVE Posted - 04/19/24

$AUTL Starter established @ $4.51; Excellent partnerships, PUDFA/data updates later this year, obe-cel pipeline & institutional investors; Now exercise some patience for its eventual acquisition by one of its partners and/or Big Pharma at a premium from current market price. Long.

User Image Mancunian Posted - 04/18/24

$AUTL just added another 10k….

User Image Magic8BallResponse Posted - 04/15/24

$AUTL Meh.... Company was not shy on dilution

User Image JerryMalone32 Posted - 04/15/24

@SocioCobb the best guy to follow for $autl is on Twitter. @DmitryKovalchuk

User Image erevnon Posted - 04/12/24

Needham reiterates Autolus Therapeutics $AUTL at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image SocioCobb Posted - 04/10/24

$AUTL Might have to get a starter here. Any solid bulls with DD I should follow? Thanks in advance...

User Image Thestocktraderhubzee Posted - 04/10/24

WATCHLIST APR 10 2024.. $AUTL Truist Securities Maintains Buy on Autolus Therapeutics, Raises Price Target to $11 $ATRC Needham Reiterates Buy on AtriCure, Maintains $46 Price Target $UDR Truist Securities Maintains Buy on UDR, Lowers Price Target to $42 $ESS Truist Securities Maintains Hold on Essex Property Trust, Lowers Price Target to $255 $EQR Truist Securities Maintains Buy on Equity Residential, Lowers Price Target to $67

User Image 1LIFE2LIVE Posted - 4 weeks ago

$AUTL Pharma giant AstraZeneca (NASDAQ:AZN) hinted it is, indeed, scanning the market for opportunities. “We are always scanning the horizon to look for new technologies that complement our portfolio, and we’re making strategic investments in new technologies and platforms that we believe have the potential to transform the future of medicine through the end of the decade and beyond” said a spokesperson for the company.

User Image schiefe13 Posted - 1 month ago

$AUTL buying zone

User Image reces1 Posted - 1 month ago

$AUTL Well that mini-bounce was short-lived.

User Image briefingcom Posted - 1 month ago

$AUTL: Autolus Therapeutics receives acceptance of MAA by the EMA for obecabtagene autoleucel https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240402071606AUTL&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Analyst Ratings
Needham Buy Apr 12, 24
Truist Securities Buy Apr 9, 24
Truist Securities Buy Mar 18, 24
Needham Buy Mar 14, 24
Needham Buy Feb 12, 24
Needham Buy Jan 22, 24
Goldman Sachs Neutral Dec 13, 23
Needham Buy Nov 29, 23
Deutsche Bank Buy Nov 9, 23